Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Zhang, H., Ryono, D.E., Devasthale, P., Wang, W., O'Malley, K., Farrelly, D., Gu, L., Harrity, T., Cap, M., Chu, C., Locke, K., Zhang, L., Lippy, J., Kunselman, L., Morgan, N., Flynn, N., Moore, L., Hosagrahara, V., Zhang, L., Kadiyala, P., Xu, C., Doweyko, A.M., Bell, A., Chang, C., Muckelbauer, J., Zahler, R., Hariharan, N., Cheng, P.T.(2009) Bioorg Med Chem Lett 19: 1451-1456
- PubMed: 19201606 
- DOI: https://doi.org/10.1016/j.bmcl.2009.01.030
- Primary Citation of Related Structures:  
3BC5 - PubMed Abstract: 
The design, synthesis and structure-activity relationships of a novel series of N-phenyl-substituted pyrrole, 1,2-pyrazole and 1,2,3-triazole acid analogs as PPAR ligands are outlined. The triazole acid analogs 3f and 4f were identified as potent dual PPARalpha/gamma agonists both in binding and functional assays in vitro. The 3-oxybenzyl triazole acetic acid analog 3f showed excellent glucose and triglyceride lowering in diabetic db/db mice.
Organizational Affiliation: 
Metabolic Diseases Chemistry, Bristol-Myers Squibb Research and Development, Princeton, NJ 08543-5400, USA.